

File No. 4-01/2013-DC (Misc. 13-Part 1)
Directorate General of Health Services
Office of Drugs Controller General (India)
(FDC Division)

FDA Bhawan, Kotla Road
New Delhi-110002
Dated:

NOTICE


20 APR 2018

Subject: Consideration of the directions of the Hon'ble Supreme Court of India in the case of 344 FDCs + 05 FDCs prohibited vide S.O. No. 705(E) to 1048 (E) dated 10.03.2016 and S.O. No. 1851(E) to 1855 (E) dated 08.06.2017 and constitution of a sub-committee for having a relook in these cases-regarding.

This is in continuation to this office notice 4-01/2013-DC (Misc. 13-Part 1) on the subject cited above whereby all the petitioners/appellants including AIDAN were requested to submit the information in the prescribed format as per Annexure A/Annexure D by 7th April 2018 till 5:00 P.M. for further action in compliance to the directions of the Hon'ble Supreme Court.

In this regard, various representations were received requesting for extending the timeline for submission of the information. The issue was considered by sub-committee in its meeting held on 20.04.2018 and it has been decided that petitioners/appellants including AIDAN may be permitted to submit the information in the prescribed format by 2nd May 2018 till 5:00 p.m.

In view of above, all the petitioners/appellants including AIDAN to note that date for the submission of information in the prescribed format is extended upto 02.05.2018 till 5:00 p.m.


(Sanjeev Kumar)
Convener

Sub-Committee of DTAB

Copy to:

1. Dr. Nilima Kshirsagar, the Chairperson, Sub-Committee of DTAB.
2. All India Drugs Action Network
3. Website of CDSCO for information and necessary action of AIDAN for complying the hearing and subsequent report submission process.
4. Indian Drugs Manufacturing Associations (IDMA)/Federation of Pharma Entrepreneurs (FOPE)